NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
Clinical Trials
29 trialsNCT03875144 2026-02-09
MESOTIP
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Suspended
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT06784765 2025-05-09
Preventive Use of PIPAC in Locally Advanced Gastric Cancer.
National Research Oncology and Transplantology Center, Kazakhstan
Phase NA Recruiting
NCT04213794 2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1 Terminated
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT03340376 2024-07-03
Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2 Active not recruiting
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT02978495 2022-12-28
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Barretos Cancer Hospital
Phase 2 Completed
NCT03287375 2022-10-07
PIPAC-OPC2
Odense University Hospital
Phase 2 Completed
NCT03604653 2022-08-03
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center, Inc.
Completed
NCT01809379 2022-07-08
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
Phase 2 Completed
NCT02475772 2022-07-08
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis
Ruhr University of Bochum
Phase 1 Completed
NCT03542669 2022-03-02
Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer
Peking University People's Hospital
Phase 1 Unknown
NCT02604784 2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT00662233 2018-10-09
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00562185 2017-11-20
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT02320448 2017-09-12
Treating Peritoneal Carcinomatosis With PIPAC
Odense University Hospital
Phase 2 Completed
NCT01659554 2017-03-10
HIPEC
Columbia University
Phase 2 Terminated
NCT03034850 2017-01-27
Thrombin Generation and Platelet Activation in CRS/HIPEC
Ziekenhuis Oost-Limburg
Completed
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed
NCT00945139 2015-07-31
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00282087 2014-12-01
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00002489 2013-06-26
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006377 2013-06-18
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002526 2012-05-15
Chemotherapy in Treating Patients With Advanced Sarcoma
Swiss Cancer Institute
Phase 2 Completed